AstraZeneca Pharma India is trading higher by 4% to Rs 1,208, extending its Friday’s 9% rally, after its board approved the delisting proposal received from the Sweden based parent AstraZeneca Pharmaceuticals AB.
AstraZeneca Pharmaceuticals AB holds 75% in AstraZeneca Pharma India, is planning to delist company’s equity shares from various bourses including the BSE and the National Stock Exchange (NSE).
Earlier this month, AstraZeneca Pharma had received by email a letter from AZP AB Sweden, promoter of the company, proposing to make a voluntary delisting offer to the public shareholders from BSE, NSE and Bangalore Stock Exchange.
The stock opened at Rs 1,224 and touched a high of Rs 1,249 on the NSE. A combined around 80,000 shares changed hands on the counter so far on the NSE and BSE.
AstraZeneca Pharmaceuticals AB holds 75% in AstraZeneca Pharma India, is planning to delist company’s equity shares from various bourses including the BSE and the National Stock Exchange (NSE).
Earlier this month, AstraZeneca Pharma had received by email a letter from AZP AB Sweden, promoter of the company, proposing to make a voluntary delisting offer to the public shareholders from BSE, NSE and Bangalore Stock Exchange.
The stock opened at Rs 1,224 and touched a high of Rs 1,249 on the NSE. A combined around 80,000 shares changed hands on the counter so far on the NSE and BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%